The price of Edwards Lifesciences Corp (NYSE:EW) shares last traded on Wall Street fell -0.68% to $88.01.
EW stock price is now -2.26% away from the 50-day moving average and 11.82% away from the 200-day moving average. The market capitalization of the company currently stands at $52.92B.
On February 02, 2024, Wells Fargo Upgraded its previous ‘Equal Weight’ rating to ‘Overweight’ on the stock keeping its target price maintained at $94, while ‘Evercore ISI’ rates the stock as ‘In-line’
In other news, Lippis Daniel J., CVP, JAPAC sold 857 shares of the company’s stock on Apr 09 ’24. The stock was sold for $79,135 at an average price of $92.34. Upon completion of the transaction, the CVP, JAPAC now directly owns 17,488 shares in the company, valued at $1.54 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 08 ’24, CVP, EMEACLA Lemercier Jean-Luc M sold 14,400 shares of the business’s stock. A total of $1,329,472 was realized by selling the stock at an average price of $92.32. This leaves the insider owning 173,849 shares of the company worth $15.3 million. A total of 1.58% of the company’s stock is owned by insiders.
During the past 12 months, Edwards Lifesciences Corp has had a low of $60.57 and a high of $96.12. As of last week, the company has a debt-to-equity ratio of 0.10, a current ratio of 3.38, and a quick ratio of 2.40.
According to the Medical Devices Company, earnings per share came in at 0.62, beating analysts’ expectations of 0.61 by 0.01. This compares to $0.65 EPS in the same period last year. The net profit margin was 23.35% and return on equity was 22.52% for EW. The company reported revenue of $1.53 billion for the quarter, compared to $1.35 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 13.78 percent. For the current quarter, analysts expect EW to generate $1.57B in revenue.
